Last Updated:
Searching
Create account to add to watchlist!

Avista Public Acquisition Corp. II - AHPA

  • Commons

    $10.00

    +0.10%

    AHPA Vol: 0.0

  • Warrants

    $0.60

    -1.64%

    AHPAW Vol: 0.0

  • Units

    $10.20

    +0.54%

    AHPAU Vol: 8.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 230.0M
Average Volume: 157.5K
52W Range: $9.75 - $10.50
Weekly %: +0.30%
Monthly %: +0.20%
Inst Owners: 0

Info

Target: Searching
Days Since IPO: 109
Unit composition:
Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-third of one redeemable warrant
Trust Size: 20000000.0M

Management

Our officers, directors and director nominees are as follows: Name ​ ​ Age ​ ​ Position ​ Thompson Dean ​ ​ 63 ​ ​ Executive Chairman and Director ​ David Burgstahler ​ ​ 52 ​ ​ President, Chief Executive Officer and Director ​ Sriram Venkataraman ​ ​ 48 ​ ​ Executive Vice President ​ Robert Girardi ​ ​ 39 ​ ​ Executive Vice President ​ Amanda Heravi ​ ​ 46 ​ ​ Investor Relations Officer ​ John Cafasso ​ ​ 48 ​ ​ Chief Financial Officer ​ Benjamin Silbert ​ ​ 50 ​ ​ General Counsel ​ William E. Klitgaard ​ ​ 68 ​ ​ Director Nominee ​ Lâle White ​ ​ 65 ​ ​ Director Nominee ​ Wendel Barr ​ ​ 59 ​ ​ Director Nominee ​ Thompson Dean has been a Director since our inception and the Executive Chairman of our board of directors since February 12, 2021. Mr. Dean is a Managing Partner and Co-Chief Executive Officer of Avista and has served in various capacities at Avista since its founding in 2005. From 1995 to 2005, Mr. Dean served as Co-Managing Partner of DLJMB and was Chairman of the investment committees of DLJMB I, DLJMB II, DLJMB III and DLJ Growth Capital Partners. Mr. Dean currently serves on the board of directors of Acino International AG, National Spine & Pain Centers and Vision Healthcare. Mr. Dean previously served on the board of directors of Charles River Laboratories, ConvaTec Group, Fisher Scientific, Nycomed, Trimb Healthcare, VWR and Zest Dental Solutions. Mr. Dean is a former trustee of Choate Rosemary Hall and The Eaglebrook School. Mr. Dean received a B.A. from the University of Virginia, where he was an Echols Scholar, and an M.B.A. with high distinction from Harvard Business School, where he was a Baker Scholar. We believe that Mr. Dean’s executive level management experience at Avista, board and advisory experience with other companies in and outside of the healthcare industry and his extensive experience in the areas of finance, strategy, international business transactions and mergers and acquisitions makes him well-qualified to serve as a member of our board of directors. David Burgstahler has been a Director since our inception and our President and Chief Executive Officer since February 12, 2021. Mr. Burgstahler is a Managing Partner and Co-Chief Executive Officer of Avista and has served in various capacities at Avista since its founding in 2005. Prior to forming Avista, he was a Partner of DLJMB from 2004 to 2005 and served in various capacities at DLJMB and its affiliates from 1995 to 2005. Prior to DLJMB, Mr. Burgstahler worked at Andersen Consulting (now known as Accenture) and McDonnell Douglas (now known as Boeing). He currently serves as on the board of directors of Arcadia Consumer Healthcare, Cosette Pharmaceuticals, Inform Diagnostics, Osmotica Pharmaceuticals (NASDAQ: OSMT), United BioSource Corporation, XIFIN and other private company boards. Mr. Burgstahler also previously served on the board of directors of AngioDynamics (NASDAQ: ANGO), Armored AutoGroup, BioReliance Corp., ConvaTec Group, Focus Diagnostics, Inc., INC Research Holdings (NASDAQ: INCR), Lantheus Holdings, MPI Research, Inc., Strategic Partners, LLC, Visant Corp., WideOpenWest (NYSE: WOW) and Warner Chilcott PLC (NASDAQ: WCRX). Mr. Burgstahler received a B.S. in Aerospace Engineering from the University of Kansas and an M.B.A. from Harvard Business School. We believe that Mr. Burgstahler’s extensive experience serving as a director for a diverse group of private and public companies, including those in the healthcare industry, makes him well-qualified to serve as a member of our board of directors. Sriram Venkataraman has been our Executive Vice President since February 12, 2021. Mr. Venkataraman is currently a Partner at Avista and originally joined Avista in 2007. Prior to joining Avista, Mr. Venkataraman was a Vice President in the Healthcare Investment Banking group at Credit Suisse which he joined in 2001. Prior to Credit Suisse, Mr. Venkataraman worked at GE Healthcare (formerly known as GE Medical Systems). Mr. Venkataraman currently serves on the board of directors of Cosette Pharmaceuticals, Inform 114 TABLE OF CONTENTS Diagnostics, National Spine & Pain Centers, Osmotica Pharmaceuticals (NASDAQ: OSMT), Solmetex and XIFIN and has previously served as s director of AngioDynamics (NASDAQ: ANGO), Lantheus Holdings (NASDAQ: LNTH), OptiNose (NASDAQ: OPTN) and Zest Dental Solutions. Mr. Venkataraman received a M.S. in Electrical Engineering from the University of Illinois, Urbana-Champaign and an M.B.A. with honors from The Wharton School at the University of Pennsylvania. Robert Girardi has been our Executive Vice President since February 12, 2021. Mr. Girardi is currently a Partner at Avista and originally joined Avista in 2010. Prior to joining Avista, Mr. Girardi was a Senior Associate at Quadrangle Group where he focused on private equity investments in the media and communications industries. Prior to joining Quadrangle, Mr. Girardi was an Associate at Bear Stearns Merchant Banking where he focused on private equity investments across a range of industries. Mr. Girardi also worked as an Analyst in the investment banking division at J.P. Morgan. Mr. Girardi currently serves on the board of directors of Arcadia Consumer Healthcare, GCM Holding Corporation and United BioSource Corporation and previously served on the board of directors of DataBank Holdings, MPI Research, Inc. and Telular Corporation. Mr. Girardi received a B.S. with highest distinction in business administration from the University of North Carolina at Chapel Hill and an M.B.A. with honors from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. Amanda Heravi has been our Investor Relations Officer since February 12, 2021. Ms. Heravi is the Head of Investor Relations at Avista and was one of the founding members of Avista in 2005. Prior to Avista, Ms. Heravi was the Director of Finance and Administration at Dorset Capital Management, which she joined in 1999, where she was responsible for investor relations and the financial, operational and administrative aspects of the fund. Prior to Dorset, Ms. Heravi worked at Montgomery Securities. Ms. Heravi received a B.A. from the University of California, Berkeley. John Cafasso has been our Chief Financial Officer since February 12, 2021. Mr. Cafasso joined Avista in May 2011. Prior to joining Avista, Mr. Cafasso was in the asset management division of Credit Suisse from 2001 to May 2011, where he was responsible for the accounting and reporting for Credit Suisse’s direct private equity funds. Prior to joining Credit Suisse, Mr. Cafasso was a Manager at KPMG, LLP in the financial services practice. Mr. Cafasso is a Certified Public Accountant and received a B.B.A. degree from Hofstra University. Benjamin Silbert has been our General Counsel and Secretary since February 12, 2021. Mr. Silbert is the Chief Administrative Officer and General Counsel at Avista and was one of the founding members of Avista in 2005. Prior to joining Avista, Mr. Silbert was at DLJMB from 2001 to 2005. While at DLJMB, Mr. Silbert acted as internal counsel on a number of investments and divestitures, in addition to fund and partnership matters. Prior to joining DLJMB, Mr. Silbert was a lawyer in the private equity and mergers and acquisitions practice groups of Morgan, Lewis & Bockius LLP, which he joined in 1996. Mr. Silbert received a B.A. from Haverford College and a J.D. from Columbia Law School. William E. Klitgaard will serve as a director following the completion of this offering. Mr. Klitgaard is an operating executive at Avista, where was retained in 2020. Mr. Klitgaard has over two decades of experience leading and advising healthcare businesses in the Healthcare IT and outsourced pharma services space. Mr. Klitgaard most recently served as President of Enlighten Health, a division of LabCorp (NYSE:LH) that focuses on innovation and creation of new information-based services utilizing core assets of LabCorp and Covance, Inc. Previously, he spent 19 years at Covance, one of the world’s largest contract research organizations, where he served for three years as Corporate Senior Vice President and Chief Information Officer, and nearly twelve years as Corporate Senior Vice President and Chief Financial Officer. Prior to his time at Covance, Mr. Klitgaard held finance leadership positions at Kenetech Corporation, a wind turbine manufacturer, and Consolidated Freightways, Inc., a freight service and logistics company. Mr. Klitgaard currently serves as a director and chairman of the audit committee of Syneos Health, Inc. (NASDAQ: SYNH), since March 2017, as a director of Inform Diagnostics, since December 2019 and as a director of XIFIN, Inc. (“XIFIN”) since January 2020. Mr. Klitgaard previously served as a director of Liaison Technologies, Bioclinica, Inc. and Certara, L.P. Mr. Klitgaard earned a B.A. in economics from the University of California at Berkeley, and a Master’s degree from the Sloan Management School, Massachusetts Institute of Technology. We believe that Mr. Klitgaard’s extensive experience leading and advising healthcare businesses makes him well-qualified to serve as a member of our board of directors. 115 TABLE OF CONTENTS Lâle White will serve as a director following the completion of this offering. Ms. White is the Executive Chairman, Chief Executive Officer and founder of XIFIN, a health information technology company that leverages diagnostic information to improve the quality and economics of healthcare. Ms. White founded XIFIN in 1997 and has over 25 years of experience in information systems development and medical billing. Ms. White lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. Ms. White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program. She has chaired the state and federal contractor committees for California Clinical Laboratory Association for years, maintaining a working relationship with the Medicare Administrative Contractors and Department of Health and Human Services. Ms. White was previously Vice President of Finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the United States, and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Ms. White currently serves as a director of Cardiff Oncology, Inc. (NASDAQ: CRDF) and previously served as a director of bioTheranostics while it was a BioMerieux subsidiary and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017. Ms. White has a B.A. in finance and an M.B.A. from Florida International University. We believe that Ms. White’s extensive executive experience with the strategic, financial and operational requirements of healthcare organizations makes her well-qualified to serve as a member of our board of directors. Wendel Barr will serve as a director following the completion of this offering. Mr. Barr has over 25 years of experience on the leading edge in the medical devices and life sciences industries. From September 2017 through November 2019, Mr. Barr was the Chief Executive Officer, President and director of Vium, Inc., a translational medicine and biotechnology company focused on improving the success of drug development through the creation of more precise and reproducible disease models. Prior to Vium, Mr. Barr was the Chief Executive Officer and director of Synteract, Inc., a full service, global contract research organization dedicated to the clinical research needs of biotechnology, medical device and pharmaceutical companies. Prior to Synteract, Mr. Barr was at Covance from 2000 through 2011, where he had multiple roles, including Chief Operating Officer and Executive Vice President. Prior to Covance, Wendel Barr was Vice President and General Manager at Marconi Medical Systems and also held several positions of increasing responsibility with GE Healthcare including General Manager from 1984 to 1999. Mr. Barr earned a B.S. in Electronics Engineering from DeVry University and a M.B.A. from the National University. We believe that Mr. Barr’s extensive experience leading companies in the medical devices and life sciences space makes him well-qualified to serve as a member of our board of directors. Number and terms of office of officers and directors Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect that our board of directors will consist of five members. Holders of our founder shares will have the right to elect all of our directors prior to consummation of our initial business combination and holders of our public shares will not have the right to vote on the appointment of directors during such time. These provisions of our amended and restated memorandum and articles of association may only be amended if approved by holders of at least 90% of our outstanding ordinary shares entitled to vote thereon. Each of our directors will hold office for a two-year term. Subject to any other special rights applicable to the shareholders, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the remaining directors of our board or by a majority of the holders of our ordinary shares (or, prior to our initial business combination, a majority of the holders of our founder shares). Pursuant to an agreement to be entered into on or prior to the closing of this offering, our sponsor, upon and following consummation of an initial business combination, will be entitled to nominate three individuals for appointment to our board of directors, as long as the sponsor holds any securities covered by the registration and shareholder rights agreement. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and restated memorandum and articles of association as it deems appropriate. Our amended and restated memorandum and articles of association will provide that our officers 116 TABLE OF CONTENTS may consist of one or more chairman of the board, chief executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. Director Independence Nasdaq listing standards require that a majority of our board of directors be independent. Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect to have two “independent directors” as defined in Nasdaq’s listing standards and applicable SEC rules. Our board of directors has determined that Mr. Klitgaard and Mr. Barr are “independent directors” as defined in the Nasdaq listing standards. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive Officer and Director Compensation None of our executive officers or directors have received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on Nasdaq through the earlier of consummation of our initial business combination and our liquidation, we will reimburse our sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. In addition, our sponsor, executive officers and directors, or their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our sponsor, executive officers or directors, or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or their respective affiliates, prior to completion of our initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, our board of directors will have three standing committees: an audit committee, a nominating committee and a compensation committee. Subject to phase-in rules and a limited exception, the rules of Nasdaq and 117 TABLE OF CONTENTS Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to phase-in rules and a limited exception, the rules of Nasdaq require that the compensation committee and the nominating committee of a listed company be comprised solely of independent directors. Under Rule 10A-3(b)(1)(iv)(A) under the Exchange Act and Nasdaq listing rule 5

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Oaktree Capital Management LP 250,000 $2,440,000 0.0% 0 0.870%
2021-11-12 Weiss Asset Management LP 924,999 $9,280,000 0.2% 0 3.217%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q FORM 10-Q 2021-11-10 https://www.sec.gov/Archives/edgar/data/1846253/000110465921137015/ahpa-20210930x10q.htm
8-K FORM 8-K 2021-09-27 https://www.sec.gov/Archives/edgar/data/1846253/000110465921119820/tm2128432d1_8k.htm
10-Q FORM 10-Q 2021-09-23 https://www.sec.gov/Archives/edgar/data/1846253/000110465921118403/ahpa-20210630x10q.htm
SC 13G AVISTA PUBLIC ACQUISITION CORP. II 2021-08-23 https://www.sec.gov/Archives/edgar/data/1846253/000110465921108557/tm2125687d4_sc13g.htm
SC 13G 2021-08-20 https://www.sec.gov/Archives/edgar/data/1846253/000093583621000474/avistapublic13g.htm
8-K FORM 8-K 2021-08-18 https://www.sec.gov/Archives/edgar/data/1846253/000110465921107385/tm2125259d1_8k.htm
SC 13G 2021-08-16 https://www.sec.gov/Archives/edgar/data/1846253/000131924421000239/AHPA_13G.htm
8-K FORM 8-K 2021-08-12 https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_8k.htm
424B4 424B4 2021-08-11 https://www.sec.gov/Archives/edgar/data/1846253/000110465921103024/tm2110146-11_424b4.htm
3 OWNERSHIP DOCUMENT 2021-08-10 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102441/xslF345X02/tm2124611-9_3seq1.xml
CERT 2021-08-10 https://www.sec.gov/Archives/edgar/data/1846253/000135445721000913/8A_cert_AHPA.pdf
EFFECT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/999999999521003105/xslEFFECTX01/primary_doc.xml
3 OWNERSHIP DOCUMENT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102438/xslF345X02/tm2124611-6_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102435/xslF345X02/tm2124611-8_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102434/xslF345X02/tm2124611-5_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102433/xslF345X02/tm2124611-7_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102432/xslF345X02/tm2124611-4_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102431/xslF345X02/tm2124611-3_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102430/xslF345X02/tm2124611-2_3seq1.xml
3 OWNERSHIP DOCUMENT 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921102428/xslF345X02/tm2124611-1_3seq1.xml
8-A12B 8-A12B 2021-08-09 https://www.sec.gov/Archives/edgar/data/1846253/000110465921101927/tm2124549d1_8a12b.htm
CORRESP 2021-08-05 https://www.sec.gov/Archives/edgar/data/1846253/000110465921101033/filename1.htm
CORRESP 2021-08-05 https://www.sec.gov/Archives/edgar/data/1846253/000110465921101031/filename1.htm
CORRESP 2021-07-28 https://www.sec.gov/Archives/edgar/data/1846253/000110465921097014/filename1.htm
S-1/A S-1/A 2021-07-28 https://www.sec.gov/Archives/edgar/data/1846253/000110465921097011/tm2110146-8_s1a.htm
UPLOAD 2021-07-06 https://www.sec.gov/Archives/edgar/data/1846253/000000000021008285/filename1.pdf
S-1 S-1 2021-06-17 https://www.sec.gov/Archives/edgar/data/1846253/000110465921082716/tm2110146-6_s1.htm
DRSLTR 2021-05-12 https://www.sec.gov/Archives/edgar/data/1846253/000110465921065202/filename1.htm
DRS/A 2021-05-12 https://www.sec.gov/Archives/edgar/data/1846253/000110465921065199/filename1.htm
UPLOAD 2021-04-14 https://www.sec.gov/Archives/edgar/data/1846253/000000000021004503/filename1.pdf
DRS 2021-03-19 https://www.sec.gov/Archives/edgar/data/1846253/000110465921039181/filename1.htm